SGLT2 inhibition improves coronary flow velocity reserve and contractility: role of glucagon signaling

SGLT2 inhibition improves coronary flow velocity reserve and contractility: role of glucagon signaling

Abstract Background SGLT2 inhibitors, a T2DM medication to lower blood glucose, markedly improve cardiovascular outcomes but the underlying mechanism(s) are not fully understood. SGLT2i’s produce a unique metabolic pattern by lowering blood glucose without increasing insulin while increasing ketone...

Full description

Bibliographic Details
Main Authors: Sven O. Göpel, Damilola Adingupu, Jue Wang, Elizaveta Semenova, Margareta Behrendt, Rasmus Jansson-Löfmark, Christine Ahlström, Ann-Cathrine Jönsson-Rylander, V. Sashi Gopaul, Russell Esterline, Li-Ming Gan, Rui-Ping Xiao
Format: Article
Language:English
Published: BMC 2024-11-01
Series:Cardiovascular Diabetology
Subjects:
Metabolic syndrome
Heart failure
SGLT2 inhibitor
Coronary flow velocity reserve
Cardiac contractility
Glucagon
Online Access:https://doi.org/10.1186/s12933-024-02491-w

Internet

https://doi.org/10.1186/s12933-024-02491-w

Similar Items